COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SKELETAL MUSCLE DEFICIENCIES

(19)

(11)

EP 2 234 625 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	30.10.2013 Bulletin 2013/44

(45)	Mention of the grant of the patent:
	11.09.2013 Bulletin 2013/37

(21)	Application number: 08861170.2

(22)	Date of filing: 17.12.2008

(51)

International Patent Classification (IPC):

A61K 31/765^(2006.01)

A61P 21/00^(2006.01)

(86)	International application number:
	PCT/US2008/087185

(87)	International publication number:
	WO 2009/079562 (25.06.2009 Gazette 2009/26)

(54)	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SKELETAL MUSCLE DEFICIENCIES ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND PRÄVENTION VON SKELETTMUSKEL-MÄNGELN COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT ET LA PRÉVENTION DE DÉFICIENCES DES MUSCLES SQUELETTIQUES

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

17.12.2007 US 14304 P

(43)	Date of publication of application:
	06.10.2010 Bulletin 2010/40

(60)	Divisional application:
	13183738.7

(73)	Proprietors:
	The Regents of the University of Michigan Ann Arbor, MI 48109-2590 (US) Phrixus Pharmaceuticals, Inc. Ann Arbor, MI 48109 (US)

(72)	Inventors:
	NG, Rainer Seattle, Washington 98125 (US) METZGER, Joseph M. Minneapolis, Minnesota 55414 (US) REEVE, Lorraine Dexter, Michigan 48130 (US) MARKHAM, Bruce Novi, Michigan 48374 (US)

(74)	Representative: Glawe, Delfs, Moll
	Patent- und Rechtsanwälte Rothenbaumchaussee 58 20148 Hamburg 20148 Hamburg (DE)

(56)

References cited: :

WO-A1-2006/100017
US-A- 5 605 687
US-A1- 2007 237 740

WO-A2-2006/091941
US-A1- 2006 012 016

COLLINS ET AL: "Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1768, no. 5, 11 April 2007 (2007-04-11), pages 1238-1246, XP022026705, BIOMEMBRANES, AMSTERDAM, NL ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2007.01.012
SCHEUERBRANDT G: "Approaching therapies for boys with Duchenne muscular dystrophy. Parent Project Muscular Dystrophy. Annual Conference in Cincinnati/Ohio, 13-16 July 2006", ACTA MYOLOGICA, vol. 25, no. 2, 1 October 2006 (2006-10-01), pages 77-97, XP001539612, GAETANO CONTE ACADEMY FOR THE STUDY OF STRIATED MUSCLE DISEASES, NAPLES; IT ISSN: 1128-2460
RYALL JAMES G ET AL: "The membrane sealant poloxamer reduces membrane permeability in tibialis anterior muscles from dystrophic mdx mice", FASEB JOURNAL, vol. 21, no. 6, A945, April 2007 (2007-04) , XP002627660, & EXPERIMENTAL BIOLOGY 2007 ANNUAL MEETING; WASHINGTON, DC, USA; APRIL 28 -MAY 02, 2007 ISSN: 0892-6638


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).